CPDR Publications

Publications banner

CPDR Publications

2015 Publications

1. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer
Jennifer Cullen, Inger L. Rosner, Timothy C. Brand, Nan Zhang, Athanasios C. Tsiatis, Joel Moncur, Amina Ali, Yongmei Chen, Dejan Knezevic, Tara Maddala, H. Jeffrey Lawrence, Phillip G. Febbo, Shiv Srivastava, Isabell A. Sesterhenn, David G. McLeod
Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29. 
Abstract

2. A Novel Genomic Alteration of LSAMP Associates with Aggressive Prostate Cancer in African American Men
Gyorgy Petrovics, Hua Li, Tanja Stümpel, Shyh-Han Tan, Denise Young, Shilpa Katta, Qiyuan Li, Kai Ying, Bernward Klocke, Lakshmi Ravindranath, Indu Kohaar, Yongmei Chena, Dezső Ribli, Korbinian Grote, Hua Zou, Joseph Cheng, Clifton L. Dalgard, Shimin Zhang, Istvan Csabai, Jacob Kagan, David Takeda, Massimo Loda, Sudhir Srivastava, Matthias Scherf, Martin Seifert, Timo Gaiser, David G. McLeod, Zoltan Szallasi, Reinhard Ebner, ThomasWerner, Isabell A. Sesterhenn, Matthew Freedman, Albert Dobi, Shiv Srivastava
EBIOM-00349

3. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods
He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG 2nd, Rastogi A, Tan SH, Yan W,Mohamed AA, Huang W, Banerjee S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Petrovics G, Dobi A, Srinivasan A.
J Transl Med. 2015 Feb 12;13:54. doi: 10.1186/s12967-015-0418-z.
Abstract

4. ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer
Nicholas B. Griner, Denise Young, Pankaj Chaudhary, Ahmed A. Mohamed, Wei Huang, Yongmei Chen, Taduru Sreenath, Albert Dobi, Gyorgy Petrovics, Jamboor K. Vishwanatha, Isabell A. Sesterhenn, Shiv Srivastava, and Shyh-Han Tan
Mol Cancer Res. 2015 Feb;13(2):368-79. doi: 10.1158/1541-7786.MCR-14-0275-T. Epub 2014 Oct 24.
Abstract

5. Prostate Cancer Marker Panel With Single Cell Sensitivity in Urine
Nickens KP, Ali A, Scoggin T, Tan SH, Ravindranath L, McLeod DG, Dobi A, Tacha D, Sesterhenn IA, Srivastava S, Petrovics G.
Prostate, 2015 Jun 15;75(9):969-75. doi: 10.1002/pros.22981. Epub 2015 Mar 23.
Abstract

6. Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
Dubovenko A, Serebryiskaya T, Nikolsky Y, Nikolskaya T, Perlina A, JeBailey L, Bureeva S, Katta S, Srivastava S, Dobi A, Khasanova T
J Cancer. 2015 Apr 1;6(6):490-501. doi: 10.7150/jca.8213. eCollection 2015.
Abstract

7. Silencing of PMEPA1 Accelerates the Growth of Prostate Cancer Cells Through AR, NEDD4 and PTEN
Li H, Mohamed AA, Sharad S, Umeda E, Song Y, Young D, Petrovics G, McLeod DG, Sesterhenn IA, Sreenath T, Dobi A, Srivastava S
Oncotarget. 2015 Jun 20;6(17):15137-49.
Abstract

2014 Publications

1. Evaluation of ERG Responsive Proteome in Prostate Cancer
Tan S-H, Furusato B, Fang XP, Fang H, Mohamed AA, Griner N, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, Sesterhenn IA, Saxena S and Srivastava S.
The Prostate. 2014; 74(1):70-89.
Abstract

2. Analysis Of The ERG Rearrangement And Protein Expression In The Progression To Castration-Resistant Prostate Cancer
Gsponer JR, Braun M, Scheble VJ, Zellweger T, Rentsch CA, Bachmann A, Perner S, Sesterhenn IA, Srivastava S, Dobi A, Bubendorf L, Ruiz C.
Prostate Cancer and Prostatic Diseases. 2014; 17(2):126-31.
Abstract

3. NKX3.1 Is A Negative Regulator Of TMPRSS2-ERG Fusions In Prostate Cancer
Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan S-H, Petrovics G, Srivastava S and Dobi A.
BMC Cancer. 2014: Jan 13;14:16.
Abstract

4. Methylation of PMEPA1, a Negative Regulator of the Androgen Receptor, Underlies its Decreased Expression in Prostate Cancer
Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Amina A, Cullen J, Srinivasan S, Dobi A, McLeod DG, Srivastava S, Yegnasubramanian S and Petrovics G.
Epigenetics 2014; Apr 2;9(6). [Epub ahead of print]

5. Long Noncoding RNA-Mediated Activation Of Androgen Receptor In Prostate Cancer
Petrovics G, Srivastava S.
Asian J Androl. 2014 May;16(3):418-9.
Abstract

6. Elevated Alkaline Phosphatase Velocity Strongly Predicts Overall Survival and the Risk of Bone Metastases in Castrate Resistant Prostate Cancer
Metwalli AR; Rosner,IL ; Cullen, J; Chen Y; Brand, T; Brassell, SA; L'esperance, JO; Porter, C; Sterbis, J, McLeod, DG.
Urologic Oncology: Seminars and Original Investigations. 2014 (in press).
Abstract

7. Increased Association Of The ERG Oncoprotein Expression In Advanced Stages Of Prostate Cancer In Filipinos
Raymundo EM, Diwa MH, Lapitan MCM, Plaza AB, Sevilleja JE, Srivastava S and Sesterhenn IA.
The Prostate. 2014 [Epub ahead of print].
Abstract

8. ERG Monoclonal Antibody (ERG-Mab, 9FY) In The Diagnosis And Biological Stratification Of Prostate Cancer: Delineation Of Minimal Epitope, Critical Residues For Binding And Molecular Basis Of Specificity.
Rastogi A, Tan S-H, Banerjee S, Sharad S, Srivastava S, Kagan J, McLeod DG, Srivastava S, Srinivasan A.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2014 (in press).

9. Nanotechnology-Based Approaches for the Development of Diagnostics, Therapeutics and Vaccines
Srinivasan A, Rastogi A, Ayyavoo V, Srivastava S.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2014 (in press).
Abstract

10. Expression of ERG Oncoprotein in Higher Grade Prostate Cancer in Caucasian American and African American Men
Farrell J, Young D, Chen Y, Degon M, Cullen J, Petrovics G, Rosner I, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA and Srivastava S.
Molecular and Clinical Oncology 2014 (in press).

11. ERG Oncoprotein Expression Status In A Multi-Ethnic Cohort Of Cap Patients From Malaysia
Kelly GM, Kong YH, Tan S-H, Dobi A, Sesterhenn IA, Srivastava S, Pathmanathan R, Tan HM, Cheong SC.
Molecular and Clinical Oncology, 2014 (in press).

12. Legends in Urology: Fathollah Keshvar "Kash" Mostofi, MD. An Interview with Isabell Sesterhenn, MD
Haas G.
Canadian Journal of Urology (21) 3 Jun 2014.

2013 Publications

1. Androgen dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and Clinical Implications
Dobi A, Sreenath T, Srivastava S.
(Book chapter). Androgen-Responsive Genes in Prostate Cancer (Edited by Zhou Wang), Springer Edition, New York USA 2013.

2. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence
Zhang C, Kallakury BV, Ross JS, Mewani RR, Sheehan CE, Sakabe I, Luta G, Kumar D, Yadavalli S, Starr J, Sreenath TL, Srivastava S, Pollard HB, Eidelman O, Srivastava M, Kasid UN.
Int J Cancer. 2013; 133:31-42.
Abstract

3. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.
Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, Srivastava S, Nelson PS, Porter CR.
The Prostate. 2013; 73:905-12.
Abstract

4. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.
Szász AM, Nyirády P, Majoros A, Székely E, Rosen P, Srivastava S, Dobi A, Szendrõi A, Kulka J, Romics I.
International Urology and Nephrology. 2013; 45:727-733.
Abstract

5. Low frequency of ERG oncogene alterations in prostate cancer patients from India. 
Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG,Srivastava S, Sesterhenn IA.
Journal of Cancer. 2013; 4:468-472.
Abstract

6. miR-30 Connects Src to EMT and ERG. 
Kao C-J, Martinez A, Shi X-B, Dobi A, deVere White RW, Kung H-J.
Oncogene. 2013 Jun [Epub ahead of print].
Abstract

7. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. 
Farrell J, Petrovics G, McLeod DG, Srivastava S.
International Journal of Molecular Sciences. 2013; 14(8):15510-31.
Abstract

8. TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. 
Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, MilosevicM, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG.
Clin Cancer Res. 2013 Sep [Epub ahead of print].
Abstract

9. Health-related quality of life for men with prostate cancer – an evaluation of outcomes 12-24 months after treatment. 
Brassell SA, Elsamanoudi SI, Cullen J, Williams ME, McLeod DG.
Urol Oncol. 2013; 31:1504-10.
Abstract

10. Anterior Tumors of the Prostate: Clinicopathologic Features and Outcomes. 
Mygatt J, Sesterhenn IA, Rosner I, Chen Y, Cullen J, Morris-Gore T, Barton J, Dobi A, Srivastava S, McLeod DG, Brassell S.
Prostate Cancer and Prostatic Diseases. In press (2013). 
Abstract

11. Evaluation of ERG Responsive Proteome in Prostate Cancer. 
Tan S-H, Furusato B, Fang XP, Fang H, Mohamed AA, Griner N, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, Sesterhenn IA, Saxena S and Srivastava S.
Prostate. 2013 Sep [Epub ahead of print].
Abstract

2012 Publications

1. Differences in Frequency of ERG Oncoprotein Expression Between Index Tumors of Caucasian and African American Patients With Prostate Cancer.
Philip Rosen, David Pfister, Denise Young, Gyorgy Petrovics, Yongmei Chen, Jennifer Cullen, Diana Böhm, Sven Perner, Albert Dobi, David G. McLeod, Isabell A. Sesterhenn, and Shiv Srivastava
Urology, 80 (4), 2012
Abstract

2. Health-related Quality of Life for Men with Prostate Cancer—an Evaluation of Outcomes 12–24 Months After Treatment.
Stephen A. Brassell, M.D., Sally I. Elsamanoudi, M.P.H., Jennifer Cullen, Ph.D., Molly E. Williams, M.D., David G. McLeod, M.D., J.D.
Urologic Oncology, [Epub ahead of print] April 2012.
Abstract

3. The Burden of Prostate Cancer in Asian Nations.
Jennifer Cullen, Sally Elsamanoudi, Stephen A. Brassell, Yongmei Chen, Monica Colombo, Amita Srivastava, and David G. McLeod
J Carcinog, 11: 7 [Epub ahead of print] March 2012.
Abstract

4. TMPRSS2-Driven ERG Expression In Vivo Increases Self- Renewal and Maintains Expression in a Castration Resistant Subpopulation.
Orla M. Casey, Lei Fang, Paul G. Hynes, Wassim G. Abou-Kheir, Philip L. Martin, Heather S. Tillman, Gyorgy Petrovics, Hibah O. Awwad, Yvona Ward, Ross Lake, Luhua Zhang, Kathleen Kelly1
PLoS ONE, 7:7 [Epub ahead of print] July 2012.
Abstract

5. Clinical Potential of the ERG Oncoprotein in Prostate Cancer.
Rosen P, Sesterhenn IA, Brassell S, McLeod DG, Srivastava S, Dobi A. 
Nature Reviews Urology, Vol 9: 131-7, March 2012.
Abstract

6. ERG Protein Expression and Genomic Rearrangement Status in Primary and Metastatic Prostate Cancer - a Comparative Study of Two Monoclonal Antibodies.
M Braun, D Goltz, Z Shaikhibrahim, W Vogel, D Bo¨hm, V Scheble, K Sotlar, F Fend, S-H Tan, A Dobi, G Kristiansen, N Wernert and S Perner
Prostate Cancer and Prostatic Diseases, 1-5, 2012
Abstract

7. N-cadherin Expression in Testicular Germ Cell and Gonadal Stromal Tumors.
Heidenberg DJ, Barton JH, Young D, Grinkemeyer M, Sesterhenn IA
Journal of Cancer, 2012; 3:381-389
Abstract

8. TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation.
Casey OM, Fang L, Hynes PG, Wassim AG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K
PLOS One, 2012, 7(7): e41668. doi:10.1371
Abstract

9. Androgen dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and Clinical Implications (Book chapter).
Dobi A, Sreenath T, Srivastava S
Androgen-Responsive Genes in Prostate Cancer (Edited by Zhou Wang), Springer Edition, New York USA 2012

2011 Publications

1. ERG Oncoprotein Portrait in Prostate Cancer: Translational Potential.
Rosen P, Sesterhenn IA, Brassell S, McLeod DG, Srivastava S, Dobi A. 
Nature Reviews Urology, in press (2012)
Abstract

2. ERG Protein Expression And Genomic Rearrangement Status In Primary And Metastatic Prostate Cancer - A Comparative Study Of Two Monoclonal Antibodies.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W,  Scheble V, Böhm D, Sotlar K, Fend F, Tan S-H, Dobi A, Wernert N, Perner S.
Prostate Cancer Prostatic Dis, [Epub ahead of print] 2012.
Abstract

3. Oncogenic Activation Of ERG, A Predominant Mechanism In Prostate Cancer.
Sreenath T, Dobi A, Petrovics G, Srivastava S.
Journal of Carcinigenesis, 10:37 [Epub ahead of print] 2011.
Abstract

4. Elevated Osteonectin/SPARC Expression in Primary Prostate Cancer Predicts Metastatic Progression.
DeRosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Siefert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G.
Prostate Cancer Prostatic Dis, [Epub ahead of print] 2011.
Abstract

5. Prostate Cancer In Men 70 Years Old Or Older, Indolent Or Aggressive: Clinicopathological Analysis And Outcomes.
Brassell SA, Rice KR, Parker PM, Chen Y, Farrell JS, Cullen J, McLeod DG.
J Urol, 185(1): 132-7, 2011.
Abstract

6. ERG Transcription Factor As An Immunohistochemical Marker For Vascular Endothelial Tumors And Prostatic Carcinoma.
Miettinen M., Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn, IA
Am J of Sur Pathol, 35:432-441, 2011
Abstract

7.ERG Oncogene Modulates Prostaglandin Signaling in Prostate Cancer Cells.
Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G, Chen Y, Sesterhenn IA, Li H, Sreenath T, McLeod DG, Dobi A, Srivastava S..
Cancer Biol Ther, 11:410-417, 2011.
Abstract

8. Prostate Cancer Gene Expression Signature Of Patients With High Body Mass Index.
Sharad S, Srivastava A, Ravulapalli S, Parker P, Chen Y, Li H, Petrovics G, Dobi A.
Prostate Cancer Prostatic Dis, 14:22-29, 2011.
Abstract

9. Prostate Cancer in Men Less Than the Age of 50: A Comparison of Race and Outcomes.
Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, Brassell SA
Urology, 78(1):110-5, 2011.
Abstract

10. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG
BJU Int, 108(3):378-85, 2011. .
Abstract

11. New data, new paradigms for treating prostate cancer patients-VI: novel hormonal therapy approaches.
Dreicer R, Bajorin DF, McLeod DG, Petrylak DP, Moul JW
Urology, 78(5 Suppl):S494-8, 2011
Abstract

12. Highlights From The Prostate Cancer Genome Report.
Tan SH, Petrovics G, Srivastava S..
Asian J Androl, 13(5):659-60, 2011.
Abstract

13. Low risk prostate cancer in men ≥ 70 years old: To treat or not to treat.
Rice KR, Colombo ML, Wingate J, Chen Y, Cullen J, McLeod DG, Brassell SA.
Urol Oncol, [Epub ahead of print] 2011.
Abstract

14. Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. 
Cullen J, Brassell SA, Chen Y, Porter C, L'esperance J, Brand T, McLeod DG
Prostate Cancer, 2011:234519. [Epub ahead of print] 2011.
Abstract

15. Words of wisdom. Re: Antibody-based detection of ERG rearrangement-positive prostate cancer.
McLeod DG, Dobi A
Eur Urol, 60(5):1123, 2011.
Abstract

16. Prostate cancer: diagnostic performance of the PCA3 urine test. 
Lee GL, Dobi A, Srivastava S. 
Nature Reviews Urology, 8(3):123-4, 2011. 
Abstract

2010 Publications

1. Prostate Cancer Risk Allele Specific for African Descent Correlates with Pathologic Stage at Prostatectomy.
Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G. 
Cancer Epidemiology, Biomarkers, & Prevention, 1:1-8, 2010.
Abstract

2. A FOXA1-binding Enhancer Regulates Hoxb13 Expression in the Prostate Gland.
McMullin RP, Dobi A, Mutton LN, Orosz A, Maheshwari S, Shashikant C, Bieberich CJ.
Proc. Natl. Acad. Sci., USA, 107:98-103, 2009.
Abstract

3. Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2–ERG Fusion Status.
K Mwamukonda, Y Chen, L Ravindranath, B Furusato, Y Hu, J Sterbis, D Osborn, I Rosner, IA Sesterhenn, DG McLeod, S Srivastava, G Petrovics 
Prostate Cancer and Prostatic Diseases, (2010) 13, 47–51.
Abstract

4. Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer.
Kevin R. Rice, Yongmei Chen, Amina Ali, Eric J. Whitman, Amy Blase, Mona Ibrahim, Sally Elsamanoudi, Stephen Brassell, Bungo Furusato, Norbert Stingle, Isabell A. Sesterhenn, Gyorgy Petrovics, Siobhan Miick, Harry Rittenhouse, Jack Groskopf, David G. McLeod, and Shiv Srivastava
Clin Cancer Res; 16(5) March 1, 2010.
Abstract

5. Prostate Cancer in Men Less Than the Age of 50: A Comparison of Race and Outcomes.
Parker PM, Rice KR, Sterbis JR, Chen Y, Cullen J, McLeod DG, Brassell SA
Urology; 2011 Mar 11. [Epub ahead of print].
Abstract

6. Patient Risk Stratification Using Gleason Score Concordance and Upgrading Among Men with Prostate Biopsy Gleason Score 6 or 7.
Serkin FB, Soderdahl DW, Cullen J, Chen Y, Hernandez J
Urol Oncol; 2010 May-Jun;28(3):302-7.
Abstract

7. ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoters.
Dobi A, Furusato B, Shaheduzzaman S, Chen Y, Vahey M, Nydam T, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S
The Open Cancer Journal; 2010, 3, 101-108.

8. ERG oncoprotein expression in prostate cancer: clonoal progression of ERG-positive tumor cells and potential for ERG-based stratification.
Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA
Prostate Cancer Prostatic Dis; 2010 Sep;13(3):228-37.
Abstract

9. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.
Ali A, Furusato B, Ts'o PO, Lum ZP, Elsamanoudi S, Mohamed A, Srivastava S, Moul JW, Brassell SA, Sesterhenn IA, McLeod DG
A Pathol Int; 2010 Oct; 60(10):667-72. doi: 10.1111/j.14440-1827.2010.02584.x.
Abstract

10. Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system.
Raymundo EM, Rice KR, Chen Y, Zhao J, Brassell SA
BJU Int; agement and outcomes in an equal access healthcare system. BJU Int. 2010 Oct 29. doi: 10.1111/j. 1464-410X.2010.09685.X. [epub ahead of print]
Abstract

11. Ets family protein. erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody.
Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S, Sreenath TL
J Cancer; 2010 Oct 25;1:197-208. 
Abstract

12. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic.
Rice K, Hudak J, Peay K, Elsamanoudi S, Travis J, Lockhart R, Cullen J, Black L, Houge S, Brassell S
Urology; 2010 Nov; 76(5):1231-8. 
Abstract

13. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. 
Abstract

2009 Publications

1. COMPARE Registry Steering Committee.: The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer.
Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT. 
Urology. 2009 Jul 7. [Epub ahead of print] (2009).
Abstract

2. The Center for Prostate Disease Research (CPDR): A multi-disciplinary approach to translational research.
Brassell SA, Dobi A, Srivastava S, McLeod DG.
Urologic Oncology: Seminars and Original Investigations, in press (2009).
Abstract

3. Periostin (POSTN): Novel stromal marker of prostate cancer progression- Comparative analysis of gene expression signatures of 3-D culture and clinical samples. 
Tsunoda T, Furusato B, Tyson DR, Ravulapalli S, Dobi A, Srivastava S, Naito S, Sesterhenn IA, Ornstein DK
The Prostate, May 28. [Epub ahead of print] (2009).

4. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.
BJU Int. 2009 Aug;104(3):310-4. [Epub ahead of print] (2009).
Abstract

5. Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells reflects TMPRSS2-ERG Fusion Status.
Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sestrehenn IA, McLeod DG. Srivastava S, Petrovics G.
Prostate Cancer and Prostatic diseases, Jul 14. [Epub ahead of print] (2009).
Abstract

6. Longterm Follow up Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrencein High-Risk Prostate Cancer Patients.
Jeremy D Gates, MD, Mark G Carmichael, MD, Linda C Benavides, MD, Jarrod P Holmes, MD,Matthew T Hueman, MD, Michael M Woll, MD, Constantine G Ioannides, PhD, Craig H Robson, MD,David G McLeod, MD, Sathibalan Ponniah, MD, George E Peoples, MD
J am Col Surg, 208 193-201 (2009).
Abstract

7. Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression.
Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML
Cancer Res, 69(13):5568-74, 2009.
Abstract

8. Clinicopathological Behavior of Single Focus Prostate Adenocarcinoma.
Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA
J Urol, 182(6):2689-94, 2009.
Abstract

9. Advances made in the Treatment of Testicular Cancer in the U.S. Military: 1946 to the Present.
Hawksworth DJ, McLeod DG, Brassell SA
Urol Oncol, 27(5):553-7. Review, 2009.
Abstract

2008 Publications

1. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer
Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA. 
Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7. 
Abstract

2. Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells
Li H, Zhou J, Miki J, Furusato B, Gu Y, Srivastava S, McLeod DG, Vogel JC, Rhim JS. 
Exp Cell Res. 2008 Jan 1;314(1):92-102. Epub 2007 Aug 23. 
Abstract

3. Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival
Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, Petrovics G.
Clin Cancer Res. 2008 Feb 1;14(3):758-63. 
Abstract

4. SELDI-TOF MS Whole Serum Proteomic Profiling With IMAC Surface Does Not Reliably Detect Prostate Cancer
McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes 
OJ: Clin Chem. 2008 Jan;54(1):53-60. Epub 2007 Nov 16. Links.
Abstract

5. Analytical Validation Of Serum Proteomic Profiling For Diagnosis Of Prostate Cancer: Sources Of Sample Bias
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ.
Clin Chem. 2008 Jan; 54(1):44-52. Epub 2007 Nov 2.
Abstract

6. TMPRSS2-ERG Fusion, A Common Genomic Alteration In Prostate Cancer Activates C-MYC And Abrogates Prostate Epithelial Differentiation
Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S.
Oncogene. 2008 Jun 9. [Epub ahead of print]
Abstract

7. Prostate Cell Cultures As In Vitro Models For The Study Of Normal Stem Cells And Cancer Stem Cells
Miki J, Rhim JS.
Prostate Cancer Prostatic Dis. 2008;11(1):32-9. Epub 2007 Nov 6. 
Abstract

8. Early Versus Delayed Hormonal Therapy For Prostate Specific Antigen Only Recurrence Of Prostate Cancer After Radical Prostatectomy
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. 
J Urol. 2008 May;179(5 Suppl):S53-9. 
Abstract

9. Do Patients With Low Volume Prostate Cancer Have PSA Recurrence Following Radical Prostatectomy?
Furusato B, Rosner IL, Osborn D, Ali A, Srivastava S, Davis CJ, Sesterhenn IA, McLeod DG.
J Clin Pathol. 2008 Jun 13. [Epub ahead of print]
Abstract

10. Editorial Comment On: New Treatment Approaches For Prostate Cancer Based On Peptide Analogues
McLeod DG. 
Eur Urol. 2008 May;53(5):898-9. Epub 2007 Dec 26.
Abstract

11. Expression Of The TMPRSS2: ERG Fusion Gene Predicts Cancer Recurrence After Surgery For Localised Prostate Cancer
Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A. 
Br J Cancer. 2007 Dec 17;97(12):1690-5. Epub 2007 Oct 30.
Abstract

12. Transcriptome Analysis of benign and malignant prostate epithelial cells in formalin fixed paraffin-embedded, whole–mounted radical prostatectomy specimens
Furusato B, Shaheduzzaman S, Petrovics S, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, 
Srivastava S, Sesterhenn, IA. 
Prostate Cancer Prostate Dis. 11: 194-197, 2008

13. Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer
Hu Y, Dobi A, Sreenath T, Cook C, Tadese AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham R, Mohamed A, Sun C, Sesterhenn IA, 
McLeod DG, Petrovics G, Srivastava S. 
Clinical Cancer Res. 2008 (in press).

14. Androgen Responsive and Refractory Prostate Cancer Cells Exhibit Distinct Curcumin Regulated Transcriptome 
Thangapazham R.L., Shaheduzzaman S., 
Kim K-H., Passi N., Vahey M., Dobi A., Srivastava S., K. Maheshwari R.
Cancer Biology and Therapy 2008 (in press).

15. PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension and Tumor 
Whitman EJ, Groskopf J, Ali A, Chen Y, Blasé A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG. 
Journal of Urology, 2008 (in press)

16. Androgen Responsive and Refractory Prostate Cancer Cells Exhibit Distinct Curcumin Regulated Transcriptome 
Thangapazham RL, Shaheduzzaman S, Kim K-H, Passi N, Vahey M, Dobi A, Srivastava S, Maheshwari R
Cancer Biology and Therapy, 2008 (in press).

17. A Feedback Loop Between the Androgen Receptor and a NEDD4 Binding Protein, PMEPA1 in Prostate Cancer Cells 
Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A, Srivastava S
J Biol Chem. 2008 Aug 14. [Epub ahead of print]
Abstract

2007 Publications

1. An assessment of the virtual conversations method for prostate cancer patient education
Harless WG, Zier MA, Duncan RC, Hudak JL, McGarvey MD, McLeod DG. 
Urol Nurs. 2007 Dec;27(6):499-506. 
Abstract

2. The design and implementations of a multidisciplinary prostate cancer clinic
Hudak JL, McLeod DG, Brassell SA, Gant DA, Shaar S, Hudak RP, Dean RC, McGarvey MD, Tulin SJ, Dozier R. 
Urol Nurs. 2007 Dec;27(6):491-8 
Abstract

3. Editorial Comment on: New Treatment Approaches for Prostate Cancer Based on Peptide Analogues
McLeod DG. 
Eur Urol. 2007 Dec 26 [Epub ahead of print] 
Abstract

4. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy
Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G. 
Urology. 2007 Dec;70(6):1225-9 
Abstract

5. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells
Miki J, Rhim JS. 
Prostate Cancer Prostatic Dis. 2007 Nov 6 [Epub ahead of print] 
Abstract

6. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer
Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV. 
Cancer. 2007 Nov 1;110(9):1973-8. 
Abstract

7. Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase.
Kim KH, Dobi A, Shaheduzzaman S, Gao CL, Masuda K, Li H, Drukier A, Gu Y, Srikantan V, Rhim JS, Srivastava S. 
Prostate Cancer Prostatic Dis. 2007;10(1):30-8. Epub 2006 Oct 31. 
Abstract

8. Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens
Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA. 
Prostate Cancer Prostatic Dis. 2007 Sep 4 [Epub ahead of print] 
Abstract

9. Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin
Li H, Kapur A, Yang JX, Srivastava S, McLeod DG, Paredes-Guzman JF, Daugsch A, Park YK, Rhim JS. 
Int J Oncol. 2007 Sep;31(3):601-6. 
Abstract

10. Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles
Li H, Gu Y, Miki J, Hukku B, McLeod DG, Hei TK, Rhim JS. 
Int J Oncol. 2007 Sep;31(3):537-44. 
Abstract

11. Silencing of Lactotransferrin Expression by Methylation in Prostate Cancer Progression
Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, Chen Y, Ehrich M, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Petrovics G, Dobi A, Srivastava S. 
Cancer Biol Ther. 2007 Jul 20;6(7) [Epub ahead of print] 
Abstract

12. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer
Richter E, Masuda K, Cook C, Ehrich M, Tadese AY, Li H, Owusu A, Srivastava S, Dobi A. 
Epigenetics. 2007 Apr-Jun;2(2):100-9. Epub 2006 Dec 27. 
Abstract

13. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. 
Cancer. 2007 Apr 1;109(7):1290-5. 
Abstract

14. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens
Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. 
Cancer Res. 2007 Apr 1;67(7):3153-61.
Abstract

15. Sarcoidosis of the prostate
Furusato B, Koff S, McLeod DG, Sesterhenn IA. 
J Clin Pathol. 2007 Mar;60(3):325-6. 
Abstract

16. Androgen receptor and prostate cancer
Richter E, Srivastava S, Dobi A. 
Prostate Cancer Prostatic Dis. 2007;10(2):114-8. Epub 2007 Feb 13. 
Abstract

2006 Publications

1. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer 
McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group.
BJU Int. 2006 Feb;97(2):247-54.
Abstract

2. Regulation of Apoptosis by a Prostate Specific and Prostate Cancer-Associated Non-coding Gene, PCGEM1
Xiaoqin Fu, Lakshmi Ravindranath, Nicholas Tran, Gyorgy Petrovics, Shiv Srivastava.
DNA Cell Biol. 2006 Mar;25(3):135-41
Abstract

3. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol 
Kumar KS, Raghavan M, Hieber K, Ege C, Mog S, Parra N, Hildabrand A, Singh V, Srinivasan V, Toles R, Karikari P, Petrovics G, Seed T, Srivastava S, Papas A.
Life Sci. 2006 Mar 27;78(18):2099-104. Epub 2006 Jan 18
Abstract

4. Phenotypic Characterization of telomerase-immortalizes primary non-malignant and malignant tumor-derived human prostate epithelial cell lines 
Yongpeng Gu, Hongzhen Li, Jun Miki, Kee-Hong Kim, Bungo Furusato, Isabell A. Sesterhenn, Wei-Sing Chu, David G. McLeod, Shiv Srivastava, Charles M. Ewing, William B. Isaacs, and Johng S. Rhim.
Exp Cell Res. 2006 Apr 1;312(6):831-43. Epub 2006 Jan 17
Abstract

5. Prostate Cancer Associated Androgen Receptor Mutation (T877A) Promotes Cell Growth and Abrogates p53 Mediated Apoptosis
Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi AL, McLeod DG, Moul JW, Srivastava S.
Oncogene. 2006 Jun 29;25(28):3905-13. Epub 2006 Apr 24
Abstract

6. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup
McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J.
J Urol. 2006 Jul;176(1):75-80
Abstract

7. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality 
Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.
Urology. 2006 Aug;68(2):342-7
Abstract

8. Quantitative expression profile of PSGR in prostate cancer 
Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. 
Prostate Cancer Prostatic Dis. 2006;9(1):56-61
Abstract

9. Distinct Effects of Annexin A7 and p53 on Arachidonate Lipoxygenation in Prostate Cancer Cells Involve 5-Lipoxygenase Transcription 
Torosyan Y, Dobi A, Naga S, Mezhevaya K, Glasman M, Norris C, Jiang G, Mueller G, Pollard H, Srivastava M. 
Cancer Res. 2006 Oct 1;66(19):9609-16
Abstract

10. The emergence of radioimmunoscintigraphy for prostate cancer 
Keane TE, Rosner IL, Wingo MS, McLeod DG 
Rev Urol. 2006;8 Suppl 1:S20-8
Abstract

11. Androgen Receptor and Prostate Cancer (Review) 
Eric Richter, Shiv Srivastava and Albert Dobi 
Prostate Cancer Prostatic Dis. 2006

12. Characterization of frequently deleted 6q locus in prostate cancer
Sun M, Srikantan V, Ma L, Li J, Zhang W, Petrovics G, Makarem M, Strovel JW, Horrigan SG, Augustus M, Sesterhenn IA, Moul JW, Chandrasekharappa S, Zou Z, Srivastava S
DNA Cell Biol. 2006 Nov;25(11):597-607
Abstract

13. Time to an Undetectable PSA Following Androgen Suppression Therapy for Post-operative or Post-radiation PSA Recurrence and Prostate Cancer-Specific Mortality
D'Amico A, Chen MH, McLeod DG, Cullen, J, Carroll P. 
Cancer, 2007

2005 Publications

1. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L
Clin Chem 51(1) 102-12, 2005.
Abstract

2. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. 
Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S.
Oncogene 2005 Mar 7.
Abstract

3. A methylation profile of in vitro immortalized human cell lines.
Liu L, Zhang J, Bates S, Li JJ, Peehl DM, Rhim JS, Pfeifer GP
Int J Oncol. 26(1): 275-85, 2005.
Abstract

4. Farnesyltransferase inhibitor effects on prostate tumor micro-enviroment and radiation survival. 
Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ
Prostate 62(1): 69-82, 2005.
Abstract

5. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. 
Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS
Anticancer Res 25(1A):1-8, 2005.
Abstract

6. Proteomics in prostate cancer.
Bañez LL, Srivastava S, Moul JW
Curr Opin Urol. 15(3):151-6, 2005.
Abstract

7. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer.
Brassell SA, Rosner IL, McLeod DG.
Curr Opin Urol. 2005 May;15(3):163-6.
Abstract

8. VEGF Inhibitors in Cancer Therapy.
Cardones AR and Bañez LL
Current Pharmaceutical Design, 11, 1-8, 2005.

9. Rationale for molecular biomarkers of prostate cancer.
Bañez LL, Srivastava S, Moul JW
Kirby, Partin, Feneley and Parsons (eds), Prostate Cancer: Principles and Practice, Taylor and Francis Medical Books, Abdington, U.K., 2005.

10. Quantitative Expression Profile of PSGR in Prostate Cancer.
Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW and Srivastava S
Prostate Cancer and Prostatic Diseases, 2005.

11. Androgen Receptor Binding Sites Identified by a GREF_GATA Model.
Katsuaki Masuda, Thomas Werner, Shilpi Maheshwari Matthias Frisch, Soyon Oh, Gyorgy Petrovics, Klaus May Vasantha Srikantan, Shiv Srivastava and Albert Dobi
J. Mol. Biol. (2005) 353, 763–771.

12. Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer.
Ward JF, Moul JW
Curr Opin Urol., 2005, 15(3): 181-6.

13. Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer.
Ward JF, Moul JW
Curr Opin Urol., 2005, 15(3): 187-95.

14. Treating the biochemical recurrence of prostate cancer after Part III: Treating strategies for biochemical recurrence of prostate cancer.
Ward JF, Moul JW
Curr Opin Urol., 2005, 15(3): 187-95.

15. Cellular Prostatic Acid Phosphatase: A Protein Tyrosine phosphatase Involved in Androgen-independent proliferation of Prostate Cancer
Suresh Veeramani, Ta-Chun Yuan, Siu-Ju Chen, Fen-Fen Lin, Juliette E Petersen, Syed Shaheduzzaman, Shiv Srivastava, Richard G. Macdonald and Ming-Fong Lin
Endocrine-Related Cancer, 2005, 12:1-18.

2004 Publications

1. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.
Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS.
Int J Oncol. 2004 Oct;25(4):1057-64.
Abstract

2. Elevated expression of PCGEM1, a prostate-specific gene with cell growth promoting function, is associated with high-risk prostate cancer patients. 
Petrovics G, Zhang W, Makarem M, Street JP, Connelly RR, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S. 
Oncogene, 23:605-611, 2004.
Abstract

3. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group. 
Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, and Soule HR: 
J Clin Oncol, 22(3):537-56, 2004.
Abstract

4. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl D:
J Urol, 171:1141-47, 2004.
Abstract

5. Race/Ethnicity and the intensity of medical monitoring under “watchful waiting” for prostate cancer. 
Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis WW, Moul JW, Fahey A: 
Medical Care, 42:239-50, 2004.
Abstract

6. Race/Ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
Shavers VL, Brown M, Potosky AL, Klabunde CN, Davis WW, Moul JW, Fahey A: 
J Gen Intern Med, 19:146-55, 2004.
Abstract

7. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence.
Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith CV, Connelly RR, McLeod DG, Moul JW: 
PCPD, 7:170-177, 2004.
Abstract

8. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D’Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH: 
J Natl Cancer Inst, 96:509-15, 2004.
Abstract

9. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. 
Penson David F, Moul Judd W, Evans Christopher P, Doyle John J [S], Gandhi Sanjay, Lamerato Lois: 
J Urol, 171(6, Part 1 of 2):2250-2254, 2004.
Abstract

10. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. 
Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR:
J Urol, 166:1322-1327, 2001.

11. Watchful Waiting and Factors Predictive of Secondary Treatment of Localized Prostate Cancer.
Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D.
J Urol, Vol 171(3) March 2004 pp 1111-1116
Abstract

12. Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy.
Moul JW et al: 
J Urol, Vol 171(3) March 2004 pp 1141-1147
Abstract

13. PSA-based biomarker for predicting mortality in prostate cancer. 
Moul JW et al: 
Am J of Urol Rev, 2(6):271-277, 2004.

14.Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy.
Amling, Christopher L.; Riffenburgh, Robert H.; Sun, Leon; Moul, Judd W.; Lance, Raymond S.; Kusuda, Leo; Sexton, Wade J.; Soderdahl, Douglas W.; Donahue, Timothy F.; Foley, John P.; Chung, Andrew K.; McLeod, David G.: 
Jour of Clin Oncology, Vol 22(3) 1 February 2004 pp 439-445
Abstract

15. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z.
Dis Markers. 2003-2004;19(4-5):185-95.
Abstract

2003 Publications

1. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M: 
JNCI, 95:1376-83, 2003.
Abstract

2. Diagnostic Potential Of Serum Proteomic Patterns In Prostate Cancer. 
Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam B-L, McLeod DG, Moul JW and Srivastava S: 
J. Urol., 170:442-6, 2003.
Abstract

3. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. 
Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. 
Urol Oncol. 21:447-55,2003.
Abstract

4. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.
Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. 
Cancer Res. 63: 4299-304, 2003.
Abstract

5. Using the percentage of biopsy cores positive for cancer, pre-treatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The Center for Prostate Disease Research nomograms. 
Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW: 
Urology, 61:589-95,2003.

6. Predictors of extracapsular extension and positive margins in African-American and Caucasian men. 
Paquette EL, Connelly RR, Sun L, Paquette LR, Moul JW: 
Urologic Oncology, 21:33-8, 2003.
Abstract

7. Pretreatment total testosterone level predicts pathologic stage in radical prostatectomy patients with localized prostate cancer. 
Massengill JC, Sun, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T:
J Urol, 169:1670-5, 2003.
Abstract

8. Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
Johnstone PA, Riffenburgh RH, Moul JW, Sun L, Wu H, McLeod DG, Kane CJ, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Chung A, Soderdahl D, Do J, Amling CL: 
Int J Radiat Oncol Biol Phys. 55:964-9, 2003.
Abstract

9. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. 
Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Banez LL, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S. 
Clin Cancer Res. 9(7):2545-50, 2003.
Abstract

10. Early prostate cancer: prevention, treatment modalities, and quality of life issues. 
Moul JW, Anderson J, Penson DF, Klotz LH, Soloway MS, Schulman CC.
Eur Urol. 44:283-93,2003.
Abstract

11. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.
Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. 
Eur Urol. 43:12-27, 2003.
Abstract

12. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. 
J Clin Oncol. 21:2163-72, 2003.
Abstract

13. A novel neoplastic primary tumor-derived human prostate epithelial cell line. 
Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Arnstein P, Taylor DO, Hukku B, Rhim JS. 
Int J Oncol. 22:1311-7, 2003.
Abstract

14. Methylation of TFPI-2 gene is not the sole cause of its silencing.
Rao CN, Segawa T, Navari JR, Xu L, Srivastava S, Moul JW, Phillips B. 
Int J Oncol. 22:843-8, 2003.
Abstract

15. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. 
Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA.
Oncol Rep. 10:223-8, 2003.
Abstract

16. Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo. 
Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK, Ruzinski JT, Rhim JS, Martin TR, Goodman RB. 
Immunol. 170:5244-51, 2003.
Abstract

17. Generation of immortal human prostate cell lines for the study of prostate cancer. 
Rhim JS. 
Methods Mol Med. 81:69-77, 2003.
Abstract

18. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. 
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW. 
Urology. 61:607-11, 2003.
Abstract

19. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer Prostate Cancer. 
Riffenburgh RH, Amling CL. 
Prostatic Dis. 6:39-44, 2003.
Abstract

20. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH Database.
Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK; 
SEARCH Database Study Group. 
Urology. 61:736-41, 2003. 
Abstract

21. SEARCH Database Study Group Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. 
Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK; 
Urology. 61:742-7, 2003.

22. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T: 
J Urol, 169:1670-5, 2003. 
Abstract

23. Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. 
Elliot SJ, Zorn BH, McLeod DG, Moul JW, Nyberg L, Striker LJ, Striker GE: 
Prostate Cancer Prostatic Dis., 6:138-42.
Abstract

24. The current art of prostate needle biopsy. 
Donahue T, Moul J: 
Contemporary Urology, 15:72-81, 2003.
Abstract

25. The role of hormonal therapy for PSA-only recurrence of PCA after local therapy. 
Moul JW, Zlotta AR: 
Contemporary Urology, 15:31-36, 2003.

26. Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen Era.
C Carter, T Donahue, L Sun, H Wu, D. McLeod, C Amling, R Lance,
J Foley, W Sexton, L Kusuda, A Chung, D Soderdahl, S Jackman, and JW. Moul
Jour Clin Oncology, Vol 21, No 21 (November 1), 2003: pp 4001-4008. 
Abstract

27. Diagnostic Potential of Prostate-specific Antigen Expressing Epithelial Cells in Blood of Prostate Cancer Patients.
Chun-Ling Gao, Sudhir K. Rawal, Leon Sun, Amina Ali, Roger R. Connelly, Lionel L. Bañez, Isabell A. Sesterhenn, David G. Mcleod, Judd W. Moul, and Shiv Srivastava
Clinical Cancer Research, Vol. 9, 2545–2550, July 2003. 
Abstract

28. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
GL Griewe, RC Dean, W Zhang, D Young, IA Sesterhenn,
N Shanmugam, DG McLeod1, JW Moul, S Srivastava
Prostate Cancer and Prostatic Diseases (2003) 6, 281–285.
Abstract

29. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. 
JW. Moul, JE Fowler, Jr.
Urology 62 (Supplement 6A), December 22, 2003.

 

2002 Publications

1. p63 Expression Profile in Normal and Malignant Prostate Epithelial Cells.
Davis LD, Zhang W, Merseburger AS, Young D, Xu LL, Rhim JS, Moul JW, Srivastava S and Sesterhenn IA. 
Anticancer Research, 22:3819-3826, 2002.

2. HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer Cells. 
Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S: 
Cancer Res. 62(23): 6812-6, 2002.

3. Androgen-Induced Expression of Endoplasmic Reticulum (ER) Stress Response Genes in Prostate Cancer Cells. 
Segawa T, Nau M, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul, Judd W, Vahey M, and Srivastava S.
Oncogene, 21, 2002.

4. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. 
Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW: 
Prostate Cancer and Prostatic Diseases. 5: 212-218, 2002.

5. Investigating the distribution of prostate cancer using three-dimensional computer simulation. 
Opell MB, Zeng J, Bauer JJ, Connelly RR, Zhang W, Sesterhenn IA, Mun SK, Moul JW and Lynch JH: 
Prostate Cancer and Prostatic Diseases. 5:204-209, 2002.

6. Molecular Markers in Prostate Cancer: The Role in Preoperative Staging.
Moul JW, Merseburger A, Srivastava S: 
Clinical Prostate Cancer 1:42-50, 2002.

7. Improved Prostate Cancer-Specific Survival and Other Disease Parameters: Impact of Prostate-Specific Testing. 
Paquette E, Sun L. Paquette LR, Connelly R, McLeod DG, and Moul JW:
Urology 60:756-759, 2002.

8. Maspin Expression Profile in Human Prostate Cancer (CaP) and in vitro induction of Maspin expression by Androgen Ablation. 
Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I. 
Clinical Cancer Research 8:1172-1177, 2002.

9. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. 
Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE and McLeod DG: 
Prostate Cancer and Prostatic Diseases. 5:304-310, 2002.

10. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. 
Koff SG, Connelly RR, Bauer JJ, McLeod DG, and Moul JW: 
Prostate Cancer and Prostatic Diseases. 5:152-158, 2002.

11. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > 40 ng/mL. 
Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, and Moul JW: 
Urol. Onc. 7:167-172, 2002.

12. Prostate-specific antigen as a marker of disease activity in prostate cancer. 
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1024-38,1042; discussion 1042, 1047-8, 1051, 2002.

13. Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis. 
Henderson CG, Griewe GL, Siegel TS, Peppas DS, Esther TA, Moul JW: 
J Urol. 168:638-9, 2002.

14. Curcumin Down-Regulates AR Gene Expression and Activation in Prostate Cancer Cell Lines. 
Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S and Rhim JS: 
Int J of Oncol., 21:825-830, 2002.

15. A novel gene DERPC located on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors. 
Sun M, Ma L, Xu L, Li J, Zhang W, Petrovics G, Makarem M, Sesterhenn I, Zhang M, Blanchette-Mackie EJ, Moul JW, Srivastava S and Zou Z: 
Molecular Medicine 8: 654-662, 2002.

16. Cadmium-induced neoplastic transformation of human prostate epithelial cells. 
Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl DM, Srivastava S, Rhim JS. 
Int J Oncol. 20:543-7, 2002.

17. Prostate biopsy quantitative histology as a staging and prognostic factor.
Moul JW. 
J Urol. 167:526-7, 2002.

18. Outcome research: prostate cancer databases. 
Moul JW:
Urol Oncol, 7:39-42, 2002.

19. Prostate-specific antigen as a marker of disease activity in prostate cancer. 
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI: 
Oncology (Huntingt), 16:1218-24, 2002.

20. Contralateral testicular biopsy procedure in-patients with unilateral testis cancer: is it indicated? 
Heidenreich A, Moul JW: 
Semin Urol Oncol, 20:234-8, 2002.

21. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. 
Taylor JA, Gancarczyk KJ, Fant GV, McLeod DG. 
Urology, 60(5):841-5, 2002.

22. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL. 
Radiology, 225:420-6, 2002.

23. Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares. 
Moul JW: 
Cancer, 95:211-4, 2002.

24. Initiation of salvage therapy for prostate cancer. 
Johnstone PA, Booth R, Riffenburgh RH, Amling CL, Kane CJ, Moul JW: 
Prostate Cancer Prostatic Dis, 5:136-43, 2002.

25. Adenocarcinoma of the prostate: an expensive way to die. 
Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T: 
Prostate Cancer Prostatic Dis, 5:164-6, 2002.

26. Emerging role of adjuvant hormonal therapy. 
McLeod DG.
Urology, 60(3 Suppl 1):13-20, 2002.

27. Overview consensus statement. Newer Approaches to androgen deprivation therapy in prostate cancer. The 2nd International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. 
Carroll PR, Kantoff PW, Balk SP, Brown MA D’amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. 
Urology, 60(3 Suppl 1):1-6, 2002.

28. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. 
See WA, Wirth MP, McLeod DG, et al., 
J Urol. 168:429-35, 2002.

29. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. 
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D and Rich NM.
Surgery, 132:213-9, 2002.

30. Diagnostic accuracy of prostate needle biopsy.
Donahue T, Moul J: 
Curr Urol Rep, 3:215-21, 2002.

31. Molecular Dissection of the Prostate Cancer Genome. 
Srikantan, V, and Srivastava S: R. Hoffman and A Heidenreich, 
eds. In Prostate Cancer, Diagnosis and Surgical Treatment, Springer-Verlag, 25-40. 2002.

2001 Publications

1. The D’Amico Article Reviewed: The CPDR/CaPSURE Recurrence Equation.
Moul JW. 
Oncology, 15:1060-1062, 2001.

2. Use of Serum Creatinine to Predict Pathologic Stage and Recurrence Among Radical Prostatectomy Patients. 
Merseburger AS, Connelly RR, Sun L, Richter E, Moul JW: 
Urology, 58:729-734, 2001.

3. The Development of Erectile Dysfunction in Men Treated for Prostate Cancer. 
Siegel T, Moul JW, Spevak M, Alvord WG, and Costabile RA: 
Journal of Urology, Vol. 165,430-435, 2001.

4. PSA Enhanced Testing and Risk Stratification for Chemoprevention Trials. 
Moul JW:
Urology, 57 (Suppl 4A): 174-177, 2001.

5. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group.
Lance RS, Freidrichs PA, Kane C, Powell CR, Pulos E, Moul JW, McLeod DG, Cornum RL, and Thrasher JB:
BJU International. Vol. 87:61-65, 2001.

6. Quantitative Expression Profile of Androgen-Regulated Genes in Prostate Cancer Cells and Identification of Prostate-Specific Genes. 
Xu LL, Su YP, LaBiche R, Segawa T, Shanmugam N, McLeod, Moul JW and Srivastava S:
Int. J. Cancer, Vol. 92:322-328, 2001.

7. Clinical Staging of Prostate Cancer: Reproducibility and Clarification of Issues.
Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul JW, Pollack A, Raghavan D, Ray P, Roach III M, Steinberg G, Stone N, Thompson I, Vogelzang N, and Vijayakumar S: 
Int. J. Cancer. (Radiat. Oncol. Invest), 96:198-209, 2001.

8. Age-Specific Reference Ranges for Prostate Specific Antigen in Young Men: Retrospective Study from the National Defense University. 
Hartzell JD, Kao TC, Holland JC, Holt SR, and Moul JW: 
The Prostate Journal, 3:36-41, 2001.

9. The Effect of Ethnicity on Biochemical Disease-Free Outcome in Patients with Prostate Cancer Treated with Definitive Radiation Therapy in an Equal-Access Health Care System: A Radiation Oncology Report of the Department of Defense Center for Prostate Disease Research. 
Johnstone P, Kane C, Sun L, Wu H, Moul JW, et al: 
Radiology, 2001.

10. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. 
Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR:
J Urol, 166:1322-1327, 2001.

11. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. 
Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D: 
J Urol, 166:1328-31, 2001.

12. A novel human cancer culture model for the study of prostate cancer. 
Yasunaga Y, Nakamura K, Ko D, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Rhim J: 
Oncogene, 20:8036-8041, 2001.

13. Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. 
Jani AB, Vaida F, Hanks, G, Asbell S, Sartor O, Moul JW, Raoch M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, and Vijayakumar S: 
Int J Cancer, 96:363-371, 2001.

14. Improvements in Pathological Staging for African-American Men Undergoing Radical Retropubic Prostatectomy During the Prostate-Specific Antigen Era – Implications for Screening a High-Risk Group for Prostate Carcinoma. 
Paquette EL, Connelly RR, Sesterhenn IA, Zhang W, Sun L, Paquette LR, Greenspan R, Mcleod DG, Moul, JW: 
Cancer, 92:2673-2679, 2001.

15. Relationship Between Obesity and Race in Predicting Adverse Pathologic Variables in Patients Undergoing Radical Prostatectomy. 
Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Freidrichs PA, Moul JW: 
Urolog, 58:723-728,2001.

16. Managing advanced prostate cancer with Viadur (leuprolide acetate implant). 
Moul JW, Civitelli K: 
Urol Nurs, 21:385-8, 393-4; quiz 395-6, 2001.

17. Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation. 
Zeng J, Bauer J, Zhang W, Sesterhenn I, Connelly R, Lynch J, Moul J, Mun SK: 
Comput Aided Surg, 6:14-21, 2001.

18. The Role of Imaging Studies and Molecular Markers for Selecting Candidates for Radical Prostatectomy. 
Moul JW, Kane CJ, and Malkowicz SB: 
Urol Clinics of North America, Volume 28, Number 3, August 2001.

19. A Novel Human Cell Culture Model for the Study of Familial Prostate Cancer. 
Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B and Rhim JS: 
Cancer Research, 61:5969-5973, August 2001.

20. Introduction to department of defense center for prostate disease research (CPDR) multicenter national prostate cancer database with 242,227 records on 11,637 men, and analysis of changes in the PSA-era. 
Sun L, Gancarczyk K, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Wu H, Xu L, Moul JW. 
Urol Oncol 2001.

2000 Publications

1. P53 Regulates the expression of tumor suppressor gene maspin. 
Zou Z, Gao C-L, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, and Srivastava S: 
J. Biol. Chem. 275:6051-6054, 2000. (News and Views, Nature Medicine: Demystifying the mehanisms of maspin, 6:374-376, 2000).

2. Inflammatory Infiltrate (Prostatitis) in Whole Mounted Radical Prostatectomy Specimens from Black and White Patients is not an Etiology for Racial Difference in Prostate Specific Antigen. 
Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, and Moul JW: 
The Journal of Urology, 163:131-136, 2000.

3. PSGR, a novel prostate specific gene with homology to a G-protein coupled receptor is overexpressed in prostate cancer. 
Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, Soppett D and Srivastava S: 
Cancer Research, 60:6568-6572, 2000.

4. Expression Profile of an Androgen Regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. 
Xu L, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, and Srivastava, S. 
J. Urol., 163:972-979, 2000.

5. Comparative Study of the Clinical Efficacy of Two Dosing Regimens of Flutamide. 
Thrasher JB, Deeths J, Bennett C, Iyer P, Dineen MK, Zhai S, Figg WD, McLeod DG: 
Mol Urol, 4 (3), 2000.

6. The Impact of Socioeconomic Status on Clinical Parameters of Radical Prostatectomy Patients in an equal access health care system.
Tarman GJ, Kane CJ, Moul JW, Thrasher JB, Foley J, White D, Riffenburgh RH, and Amling CL: 
Urology 56: 1016-1020, 2000.

7. PCGEMI, A novel prostate specific gene is overexpressed in prostate cancer. 
Srikantan V, Zou Z, Petrovics G, Xu LL, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzzard GS, Mostofi FK, McLeod DG, Moul JW, and Srivastava S: 
Proc. Natl. Acad. Sci. USA 97:12216-12221, 2000.

8. Prostate Cancer in men 50 years of age of less: A review of the Department of Defense Center for Prostate Disease Research (CPDR) Multicenter Prostate Cancer Database. 
Smith CV, Bauer JJ, Connelly RR, Seay T, Kane CJ, Foley J, Thrasher JB, Kusuda L, and Moul JW: 
Journal of Urology Vol. 164: 1964-1967, 2000.

9. The role of pretreatment serum albumin to predict pathological stage and recurrence among radical prostatectomy cases.
Richter E, Connelly RR and Moul JJ: 
Prostate Cancer and Prostatic Diseases Vol. 3: 186-190, 2000.

10. In vitro human cell culture models for the study of prostate cancer. 
Rhim JS: 
Prostate Cancer and Prostatic Diseases, 3:229-235, 2000.

11. Prostate Specific Antigen Levels in Young White and Black Men 20 to 45 Years Old. 
Preston DM, Levin LI, Jacobson DJ, Jacobsen SJ, Rubertone M, Holmes E, Murphy GP and Moul JW:, 
Urology, 56:5, 2000.

12. Treatment of Metastatic Prostate Cancer.
Moul JW: 
Brazil J Urology, 26(2): 132-145, 2000.

13. Targeted screening for prostate cancer in African-American men. 
Moul JW: 
Prostate Cancer and Prostatic Diseases, 3:248-255, 2000.

14. Screening for Prostate Cancer in African Americans. 
Moul JW: 
Current Urology Reports 1: 57-64, 2000.

15. Prostate Specific Antigen only Progression of Prostate Cancer. 
Moul JW: 
The J. Urology, 163: 1632-1642, 2000.

16. Management of prostate specific antigen increase after definitive treatment of prostate cancer. 
Moul JW: 
AUA News, October 2000.

17. Hormonal Therapy Options for Biochemical Recurrence of Prostate Cancer after Local Therapy. 
Moul JW: 
Molecular Urology, 4:267-271, 2000.

18. The Role of Imaging Studies and Molecular Markers for Selecting Candidates for Radical Prostatectomy. 
Moul JW, Kane CJ, and Malkowicz SB: 
Urol., Clinics of North America, 2000.

19. Gynecomastia in Patients with Prostate Cancer: A Review of Treatment Options. 
McLeod DG, Iverson P: 
Urology, 213-720, 2000.

20. Multicenter Patient Self-Reporting Questionnaire on Impotence, Incontinence and Stricture After Radical Prostatectomy.
Kao TC, Cruess DF, Garner D, Foley J, Seay T, Friedrichs Jr. P, Brantley T, Mooneyhan TR, McLeod DG, and Moul JW: 
The Journal of Urology, 163, 858-864, 2000.

1999 Publications

1. Benign Prostatic Hyperplasia: New Concepts for the Millennium. 
Zorn B, Bauer JJ, and Moul JW:
The American Journal of Managed Care, 5: 911-922, 1999.

2. Expression Profile of an Androgen Regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. 
Xu L, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, and Srivastava S: 
J Urol, 3:47-70, 1999.

3. p53 and BCL-2 Immunohistochemistry in Pretreatment Prostate Needle Biopsies to Predict Recurrence of Prostate Cancer after Radical Prostatectomy. 
Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava S, and Moul JW: 
J Urol, 162:2040-2045, 1999.

4. Molecular progression of prostate cancer. 
Srivastava S, and Moul JW: 
Advances in Oncobiology. Jai Press Inc. 3:155-187, 1999.

5. Chromosome 6q alterations in human prostate cancers. 
Srikantan V, Sesterhenn IA, Davis L, Hankins GR, Avallone FA, Livesey JR, Connelly R, Mostofi FK, McLeod DG, Moul JW, Chandrasekharappa SC and Srivastava S:
Int. J. Cancer, 84:331-335, 1999.

6. Prostate-Specific Antigen to Predict Outcome of External-Beam Radiation for Prostate Cancer: Walter Reed Army Medical Center Experience: 1988-1995. 
Preston DM, Bauer JJ, Connelly RR, Leifer ES, Halligan J, Sawyer T, McLeod DG, Moul JW: 
Urology, 53: 131-138, 1999.

7. Update of Clinical and Basic Science Research on Prostate Cancer from the Department of Defense Center for Prostate Disease Research (DOD-CPDR). 
Moul JW: 
Prostate Cancer and Prostatic Diseases 2(suppl. 3): S22, 1999.

8. The Foster/Nichols Article Reviewed (Clinical Stage 1 NSGCT). 
Moul JW: 
Oncology, 13(12): 1700-1703, 1999.

9. Rising PSA After Local Therapy Failure: Immediate vs Deferred Treatment. 
Moul JW: 
Oncology, 13(7): 985-999, 1999.

10. Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy. 
Moul JW: 
European Urology, 35: 399-407, 1999.

11. A PSA cutoff on 4 is too high for many men. 
Moul JW: 
Contemporary Urology 15-33, July, 1999.

12. Prostate Cancer in the Late 1990's: Hormone Refractory Disease Options. 
Moul JW, Lipo DR: 
Urologic Nursing, 19(2):125-131, 1999.

13. Racial Differences in Tumor Volume and Prostate Specific Antigen among Radical Prostatectomy Patients. 
Moul JW, Connelly RR, Mooneyhan RM, Zhang W, Sesterhenn IA, Mostofi FK, and McLeod DG:
The Journal of Urology, 162: 394-397, 1999.

14. Blinded Evaluation of Reverse-Transcriptase Chain Reaction (RT-PCR) Prostate Specific Antigen (PSA) Peripheral Blood Assay for Molecular Staging of Prostate Cancer. 
Gao C, Maheshwari S, Dean RC, Tatum L, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW: 
Urology, 53:714-721, 1999.

15. Detection of Circulating PSA-expressing Prostatic Cells in the Bone Marrow of Radical Prostatectomy Patients by Sensitive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). 
Gao C, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW: 
J Urol, 161: 1076-1076, 1999.

16. 3-D Computer Simulated Prostate Models Lateral Prostate Biopsies Increase the Detection Rate of Prostate Cancer. 
Bauer JJ, Zeng J, Weir J, Zhang W, Sesterhenn IA, Connelly RR, Mun SK, Moul JW:
Urology, 53:961-967, 1999.

1998 Publications

1. Reference Ranges for Serum Prostate Specific Antigen (PSA) in Black and White Men Without Cancer. 
Weinrich MC, Jacobsen S, Weinrich SP, Moul JW, Oesterling JE, Jacobson D, Wise R: 
Urology, 52:967-973, 1998.

2. Use of Prostate Specific Antigen in Black Men: Age-Adjusted Reference Ranges for Maximal Cancer Detection. 
Moul JW: 
J Nat Med Assoc., 90(11-suppl.): 1-2, 1998.

3. Treatment Options for Prostate Cancer: Part 1 - Stage, Grade, PSA, and Changes in the 1990's. 
Moul JW: 
Am J Manage Care, 4:1031-1036, 1998.

4. Treatment Options for Prostate Cancer: Part 2 - Early and Late Stage and Hormone Refractory Disease. 
Moul JW: 
Am J Manage Care. 4:1171-1180, 1998.

5. Prostate cancer in African-American men. 
Moul JW: 
Prostate Cancer and Prost. Dis. 1:109-118, 1998.

6. Pelvic Muscle Rehabilitation in Males Following Prostatectomy. 
Moul JW: 
Urologic Nursing, 18(4): 296-301, 1998.

7. Curability of Prostate Cancer in African Americans: Implications for Neoadjuvant/Adjuvant Hormone Therapy. 
Moul JW: 
Mol. Urol., 2:209-213, 1998.

8. Contemporary hormonal management of advanced prostate cancer. 
Moul JW: 
Oncology 12:499-505, 1998.

9. Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy. 
Moul JW, Mooneyhan RM, Kao TC, McLeod DG, Cruess DF: 
Prost. Can. Prost Dis., 5:242-249, 1998.

10. Metastatic Bone Pain Associated with Prostate Cancer. 
Moul JW, Lipo DR: 
Home Hlth Care Consult. 5:2-12, 1998.

11. The contemporary value of pretreatment prostate acid phosphatase (PAP) to predict pathologic stage and recurrence in radical prostatectomy patients. 
Moul JW, Connelly RR, Perahia B, McLeod DG: 
J Urol, 159:935-40, 1998.

12. Perineal seeding of prostate cancer as the only evidence of recurrence 14 years after needle biopsy and radical prostatectomy molecular correlation. 
Moul JW, Bauer JJ, Srivastava S, Colon E, Sesterhenn IA, Ho CK, McLeod DG: 
Urology 51:158-60, 1998.

13. p53 protein and gene alterations in pathological stage C prostate carcinoma (letter). 
Moul JW, Bauer JJ, Sesterhenn IA, Stackhouse GB, Srivastava:
J Urol, 159:1648-9, 1998.

14. Efficacy of multiple administration of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. 
Li Z, Rakkar A, Katayose Y, Kim M, Shanmugam N, Srivastava S, Moul JW, McLeod DG, Cowan KH, and Seth P: 
Gene Therapy, 5:605-613, 1998.

15. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A. Sesterhenn IA, Mostofi FK, Moul JW: 
Cancer, 83:1002-11, 1998.

16. Molecular analysis of p16 (Ink4)/CDKN2 and p15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. 
Heidenreich A. Gaddipati JP, Moul JW, Srivastava S: 
J Urol, 159:1725-30, 1998.

17. Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumors. 
Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW:
Int. J Androl, 21:283-8, 1998.

18. Immunohistochemical and mutational analysis of the p53 tumor suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. 
Heidenreich A, Schenkman NS, Sesterhenn IA, Mostofi KF, Moul, JW, Srivastava S, Engelman, UH: 
APMIS (Denmark), 106(1) 90-99, 1998.

19. Molecular analysis of p16Ink4/CDKN2 and p15Ink4B/MTS2 Genes in Primary Human Testicular Germ Cell Tumors. 
Heidenreich A, Gaddipati JP, Moul JW, and Srivastava S: 
J. Urol., 159:1725-1730, 1998.

20. A Long-term Study of the Efficacy of Treatment of Localized Prostate Cancer. 
Friedrichs MD, Moul JW, Wojcik B, Donatucci C, Optenberg S, Kreder K, Thompson IM: 
Urol Oncol., 1998.

21. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
Bettencourt M, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW: 
J Urol, 160:459-465, 1998.

22. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. 
Bauer JJ, Srivastava S, Connelly RR, Sesterhenn IA, Preston DM, McLeod DG, Moul JW: 
Urology, 51:970-6,1998.

23. Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. 
Bauer JJ, Connelly RR, Sesterhenn IA, Srivastava S, McLeod DG, Moul JW: 
Mil Med., 163:615-9, 1998.

24. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. 
Bauer JJ, Connelly RR, Sesterhenn IA, DeAusen J, Srivastava S, McLeod DG, Moul JW: 
J Urol, 159(3): 929-933, 1998.

1997 Publications

1. p53 tumor suppressor gene alterations in prostate cancer and potential p53 gene therapy approaches. 
Srivastava S, Moul JW:
Molecular Urol.1:151-158, 1997.

2. Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. 
Preston DM, Zeidman SM, Spevak M, Moul JW, Costabile RA: 
Tech. In Urol., 3:51-53, 1997.

3. PSA thresholds for prostate cancer detection (letter). 
Moul JW: 
JAMA, 278:699, 1997.

4. Molecular genetics of the testicular cancer. 
Moul JW: 
J Urol, 157:1552-1553, 1997.

5. Increased risk of prostate cancer in African-American men.
Moul JW:
Molecular Urol. 1:119-127, 1997.

6. Epidemiology and screening for prostate cancer.
Moul JW: 
Am. J. Managed Care.3(8):1200-1205, 1997.

7. Editorial: Radical prostatectomy and cryotherapy - some answers, more questions.
Moul JW
Journal of Urology, 157:256-257, 1997.

8. Prostate cancer-1997: Practicing what we preach. 
Moul JW: Editorial:
J Urol, 158:1859-60, 1997.

9. What is proper cancer care in the era of managed care?
Moul JW: 
Editorial to: Oncology, 11(1):72-78, 1997.

10. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. 
Moul JW: 
Editorial comment to: J Urol, 158:154, 1997.

11. Prostate cancer and African-American men. 
Moul JW: 
Editorial comment to: Oncology, 11(5):611-618, 1997.

12. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: Ethnic variations. 
Moul JW: 
Editorial comment to: J Urol, 157:911-912, 1997.

13. Outcome of African American Men Screened for Prostate Cancer: The Detroit Education and Early Detection Study. 
Moul JW: 
Editorial comment to: J Urol, 158: 149, 1997.

14. A better definition of advanced prostate cancer for today’s patients.
Moul JW: 
Contemp Urol, pp.15-31. Dec. 1997.

15. Age-specific reference ranges for serum prostate-specific antigen in black men. 
Morgan TO, Jacobsen SJ, McCarthy WF, Moul JW: 
Urol. Digest, 3(1):1997.

16. Enzyme/producing gene therapy approach for breast cancer using a recombinant adenovirus expressing E coli cytosine deaminase.
Li, Z, Shanmugam N, Katayose, D., Huber, B, Srivastava, S, Cowan, K and Seth, P. 
Cancer Gene Therapy 4:113-7,1997

17. Suramin Keratosis: a Unique Skin Eruption in a Patient Receiving Suramin for Metastatic Prostate Cancer. 
Kenner JR, Sperling LC, Waselenko J, Dawson N, Sau P, Moul JW: 
J Urol, 158:2245-46, 1997.

18. The influence of ejaculation on serum levels of prostate specific antigen.
Heidenreich A, Vorreuther R, Neubauer S, Westphal J, Moul JW, Englemann UH: 
Journal of Urology, 157:209-211, 1997.

19. Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours.
Heidenreich A, Srivastava S, Engelman, UH: 
Scan J Urol Nephrol (Sweden), 389-92, 1997.

20. Prognostic risk factors in low stage testicular germ cell tumors.
Heidenreich A, Sesterhenn IA, Moul JW: 
Cancer, 79:1641-1645, 1997.

21. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I non-seminomatous germ cell tumors. 
Heidenreich A, Schenkman N, Sesterhenn IA, Mostofi FK, Heidenreich B, Moul JW: 
J Urol, 158:620-625, 1997.

22. Clinical Stage I Mature Teratoma of the Testis - Retroperitoneal Lymphadenectomy or Surveillance?
Heidenreich A, Neubauer S, Mostofi FK, Sesterhenn IA, Moul JW, Engelmann UH: 
Urology 36:440-4, 1997.

23. Synchronous Bilateral Testicular-Tumor Nonseminomatous Germ-Cell Tumors and Contralateral Benign Tumors.
Heidenreich A, Moul JW, Srivastava, S, Engelman UH: 
Sci J Urol, N, 31:389-392, 1997.

24. The role of retroperitoneal lymphadenectomy in patients with mature teratoma of the testis. 
Heidenreich A, Moul JW, McLeod DG, Mostofi FK, Engelmann UH: 
Journal of Urology, 157:160-163, 1997.

25. Gossypiboma (retained surgical sponge) and recurrent bladder neck contracture following radical retropubic prostatectomy and bilateral pelvic lymph node dissection. 
Heffernan JP, Heidenberg HB, Irby PB, and Moul JW: 
J Urol, 157:1356-57, 1997.

26. Mutations of the p16 gene product are rare in prostate cancer. 
Gaddipati JP, McLeod DG, Sesterhenn IA, Hussian CJ, Tong YA, Seth P, Dracopoli NC, Moul JW, and Srivastava S: 
The Prostate, 30:188-194, 1997.

27. Prostate-specific antigen detected prostate cancer (Stage T1c): An analysis of whole-mount prostatectomy specimens. 
Douglas TH, Sesterhenn IA, Mostofi FK, Moul JW, and McLeod DG:
The Prostate 32:59-64, 1997.

28. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. 
Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P, Cowan K: 
Oncogene 16(2):265-272, 1997

29. Benign prostatic hyperplasia (BPH):New concepts in the 1990's.
Bauer JJ, Zorn B, Moul JW: 
Fed. Pract. 14(4):24-36, 1997.

30. Prostatitis: Diagnostic and treatment challenges. 
Bauer JJ, Moul JW.
Fed. Pract. 14:10-15, 1997.

31. Biostatistical modeling using traditional variables and genetic biomarkers for predicting risk for prostate cancer recurrence after radical prostatectomy. 
Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt MC, McLeod DG, Srivastava S, Moul JW: 
Cancer, 79:952-62, 1997.

32. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector.
Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P, and Srivastava S: 
Int. J. Cancer, 71:377-382, 1997.

1996 Publications

1. Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis. 
Schwartz BF, Auman R, Peretsman SJ, Moul JW, Deshon GE, Hernandez J, Rozanski TA, Thrasher JB: 
J. Surg. Oncol, 61:131-133, 1996.

2. Protein expression of p53, bcl-2 and Ki-67 (MIBI) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. 
Moul, JW, Bettencourt, MC, Sesterhenn, IA, Mostofi, FK, McLeod, DG, Srivastava, S, and Bauer, JJ: 
Surgery, 120:159-167, 1996.

3. Management of Prostate Cancer for Primary Care: Epidemiology and Screening. 
Moul JW: 
Fed Prac (Supplement) 1996, pp 3-8.

4. Cathepsin-D and Epidermal Growth Factor Receptor (EGFR), immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. 
Moul JW, MayGarden SJ, Ware JL, Mohler JL, Maher PD, Schenkman NS, and Ho CK: 
J Urol, 155:982-985, 1996.

5. Prognostic factors in low-stage non-seminomatous testicular cancer.
Moul JW, Heidenreich A: 
Oncology, 10 (9): 1359-1374, 1996.

6. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal-access health care system. 
Moul JW, Douglas TH, McCarthy WF, and McLeod DG: 
J Urol 155:1667-1673, 1996.

7. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.
Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW: 
Urology, 48(Suppl.) S76, 1996.

8. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. 
Morgan TO, McLeod DG, Leifer ES, Moul JW, Murphy GP: 
The Prostate (Suppl. 7):58-63, 1996.

9. Age-specific reference ranges for prostate specific antigen-based detection of prostate cancer in African American men. 
Morgan TO, Jacobsen SJ, McCarthy WF, McLeod DG and Moul JW: 
New England Journal of Medicine, 335:304-310, 1996.

10. Renal milk of calcium: contraindication to extracorporeal shock wave lithotripsy.
Heidenreich A, Vorreuther R, Krug B, Moul JW, Engelmann UH. 
Techniques in Urology, 2:121-125, 1996.

11. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?
Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, and Srivastava S: 
Urology 48:971-979, 1996.

12. Teleconferencing as a method of educating men about managing advanced prostate cancer and pain. 
Glajchen M, and Moul JW: 
J Psychosocial Oncol, 14 (2):73-87, 1996.

13. Patient selection for experimental adjuvant therapy after radical prostatectomy (letter). 
Douglas TH, McCarthy WF, McLeod DG, and Moul JW: 
Urology, 47:284-285, 1996.

14. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. 
Bettencourt M, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, and Moul JW: 
J Urol, 156:1064-1068, 1996.

15. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients.
Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, and Moul JW: 
J Urol, 156: 1511-1516, 1996.

16. Review of current detection and treatment options. 
Bauer JJ, McLeod DG, and Moul JW: 
Prostate cancer: Fed Prac Oct, pp 72-90, 1996.

17. Prostate cancer: Diagnosis, treatment and experience at one tertiary military medical center, 1989 and 1994. 
Bauer JJ, McLeod DG, and Moul JW: 
Milit Med, 161:646-653,1996.